EQRx company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Acq - Pending | Acquired

Total Raised




About EQRx

EQRx is a biotechnology company focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. Leveraging advances in science and technology to bring treatments for life threatening and chronic diseases to people more efficiently and cost-effectively, EQRx intends to offer its therapies at dramatically lower prices compared to today’s innovative medicines.

EQRx Headquarters Location

50 Hampshire Street

Cambridge, Massachusetts, 02139,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing EQRx

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned EQRx in 2 CB Insights research briefs, most recently on Apr 29, 2020.

Expert Collections containing EQRx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EQRx is included in 2 Expert Collections, including Unicorns- Billion Dollar Startups.


Unicorns- Billion Dollar Startups

1,182 items


Biopharma Tech

838 items

Latest EQRx News

SoftBank takes stakes in Nu Holdings, EQRX, SPACs

Aug 15, 2022

Carl Court SoftBank ( OTCPK:SFTBY ) ( OTCPK:SFTBF ) took new stakes in Brazilian fintech Nu Holdings (NYSE: NU ), acquiring 22M shares, and pharmaceutical firm EQRX (NASDAQ: EQRX ) with 800K shares. It also took new stakes in a number of SPACs during Q2, as disclosed in its latest 13F filing. SoftBank was listed as a pre-IPO investor when Nu Holdings ( NU ) went public through an IPO in December 2021; however, NU wasn't listed in SoftBank's ( OTCPK:SFTBY ) holdings as of March 31, 2022. The tech company that has a huge investment arm acquired 2.7M shares of special purpose acquisition company ("SPAC") Aurora Acquisition (NASDAQ: AURC ), 7.5M shares of Far Peak acquisition (NYSE: FPAC ), 2.2M units of SVF Investment (NASDAQ: SVFAU ), and 1.0M shares of SVF Investment Corp. 2 (NASDAQ: SVFB ). SoftBank ( OTCPK:SFTBY ) also made a new investment in Shift Technologies (NASDAQ: SFT ), an ecommerce platform for buying and selling used cars, with 2.07M shares. Earlier this month (Aug. 8), SoftBank ( OTCPK:SFTBY ) started to sell some of its shares in SoFi Technologies (NASDAQ: SOFI ) and may sell its entire 9% stake in the company. Recommended For You

EQRx Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

EQRx Rank

  • When was EQRx founded?

    EQRx was founded in 2020.

  • Where is EQRx's headquarters?

    EQRx's headquarters is located at 50 Hampshire Street, Cambridge.

  • What is EQRx's latest funding round?

    EQRx's latest funding round is Acq - Pending.

  • How much did EQRx raise?

    EQRx raised a total of $700M.

  • Who are the investors of EQRx?

    Investors of EQRx include CM Life Sciences III, Nextech Invest, Casdin Capital, Section 32, Google Ventures and 5 more.

  • Who are EQRx's competitors?

    Competitors of EQRx include Alnylam Pharmaceuticals and 5 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Konova Logo

Konova offers anti-obesity drug development


SynDevRx has developed a technology that increases the activity and safety of small molecule drugs using a conjugation technique. The company's technology increases a drug's therapeutic index by concentrating activity at the disease site. It provides small molecules with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile. SynDevRx's lead drug candidate SDX-7320 targets the oncology market, and inhibits MetAP2 - an enzyme which independent research has shown to be key to tumor growth, proliferation and metastasis.

CNS Response Logo
CNS Response

CNS is a company developing and marketing a neurophysiological bio-marker system which can objectively measure the physiological effects of psychiatric drugs on humans.


Allozyne is a protein optimization company committed to the development of improved biological therapeutics to treat multiple areas of unmet medical need. Allozyne's two technology platforms enable the incorporation of amino acids analogues, at any specified position, into existing biologics leading to improved efficacy, tolerability and pharmacology.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.